GeneDx Holdings (WGS) Cash & Current Investments (2020 - 2026)

GeneDx Holdings has disclosed Cash & Current Investments across 7 years of filings, most recently posting $170.7 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 7.24% year-over-year to $170.7 million; the TTM figure through Mar 2026 stood at $170.7 million (up 7.24% YoY), while the FY2025 annual figure was $171.3 million, up 21.32% from the prior year.
• Cash & Current Investments held at $170.7 million in Q1 2026, from $171.3 million in the prior quarter.
• Over the last five years, Cash & Current Investments for WGS reached as high as $315.0 million in Q1 2022 and fell as low as $106.9 million in Q2 2024.
• The 5-year median for Cash & Current Investments is $155.1 million (2025), against an average of $164.6 million.
• The widest YoY moves for Cash & Current Investments: up 973.92% in 2022, down 69.06% in 2022.
• A 5-year view of Cash & Current Investments shows it stood at $123.9 million in 2022, then climbed by 5.01% to $130.1 million in 2023, then gained by 8.48% to $141.2 million in 2024, then grew by 21.32% to $171.3 million in 2025, then dropped by 0.35% to $170.7 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $170.7 million, $171.3 million, and $155.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.